肝动脉栓塞化疗联合索拉菲尼治疗原发性肝癌临床研究.docVIP

肝动脉栓塞化疗联合索拉菲尼治疗原发性肝癌临床研究 　　[摘要]目的 探讨肝动脉栓塞化疗（TACE）联合索拉菲尼治疗原发性肝癌的临床效果。方法 选择2009年1月～2011年4月鞍山市肿瘤医院收治的中晚期原发性肝癌患者114例，随机分为试验组和对照组，每组各57例。试验组采用TACE联合索拉菲尼治疗，对照组单纯采用TACE治疗。观察两组的治疗效果、甲胎蛋白水平以及卡氏评分改善情况；观察两组不良反应发生情况、皮肤反应以及5年内生存率。结果 试验组总有效率（73.68%）显著高于对照组（49.12%）（P0.01）。治疗后，两组患者甲胎蛋白浓度变化和卡氏评分均较治疗前显著改善（P0.05），且试验组明显优于对照组（P0.01）。治疗期间，两组患者均未发生严重不良反应，试验组皮肤反应发生率（64.9%）明显高于对照组（10.5%）（P0.01）。试验组患者5年内的生存率均显著高于对照组（P0.01）。结论 采用肝动脉栓塞化疗联合索拉菲尼治疗原发性肝癌可以取得显著的近期疗效，可明显改善患者的甲胎蛋白?舛缺浠?和卡氏评分，不良反应较轻微，远期疗效满意，值得在临床上大力推广。 　　[关键词]肝动脉栓塞化疗；索拉菲尼；原发性肝癌；临床疗效 　　[中图分类号] R735.7 [文献标识码] A [文章编号] 1674-4721（2016）11（a）-0077-03 　　[Abstract]Objective To evaluate the clinical efficacy of transcatheter arterial chemoembolization （TACE） combined with Sorafenib in the treatment of primary hepatic carcinoma.Methods One hundred and fourteen patients with advanced primary hepatic carcinoma admitted in Tumor Hospital of Anshan City from January 2009 to April 2011 were randomly divided into experimental group and control group，57 cases in each group.Patients of the experimental group were treated with TACE combined with Sorafenib，and patients of the control group were treated with TACE alone.The therapeutic effect，concentration of AFP，and Karnofsky score of the two groups were observed；adverse reaction，skin reaction and 5-year survival rate were observed.Results The total effective rate in the experimental group （73.68%） was significantly higher than that in the control group （49.12%） （P0.01）.After treatment，the AFP concentration and Karnofsky score of the two groups were significantly improved compared with before treatment，and the experimental group was better than the control group （P0.01）.During the treatment，there was no serious adverse reactions were observed in the two groups.The incidence of skin reaction in the experimental group（64.9%） was significantly higher than that in the control group（10.5%） （P0.01）.The 5 years survival rate of the patients in the trial group was higher than that in the control group （P0.01